• Publications
  • Influence
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
TLDR
The presence of multiple metabolic disorders is associated with a potentially progressive, severe liver disease and the increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades. Expand
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
TLDR
A simple scoring system accurately separates patients with nonalcoholic fatty liver disease with and without advanced fibrosis, rendering liver biopsy for identification ofAdvanced fibrosis unnecessary in a substantial proportion of patients. Expand
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
TLDR
It is concluded that NAFLD, in the presence of normoglycemia and normal or moderately increased body weight, is characterized by clinical and laboratory data similar to those found in diabetes and obesity. Expand
Association of nonalcoholic fatty liver disease with insulin resistance.
TLDR
Nonalcoholic fatty liver disease is associated with insulin resistance and hyperinsulinemia even in lean subjects with normal glucose tolerance, and genetic factors that reduce insulin sensitivity and increase serum triglyceride levels may be responsible for its development. Expand
A position statement on NAFLD/NASH based on the EASL 2009 special conference.
TLDR
This poster presents a meta-modelling procedure called “spot-spot analysis” that allows for the direct comparison of the response of the immune system to various types of carbohydrates and its role in disease. Expand
Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study
TLDR
NAFLD is highly prevalent in the general population, is not associated with SLD, but is associated with many features of the metabolic syndrome. Expand
Insulin resistance: A metabolic pathway to chronic liver disease
TLDR
The ability of insulin‐sensitizing, pharmacological agents to treat NAFLD by reducing IR in the liver (metformin) and in the periphery (thiazolidinediones) are discussed. Expand
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.
TLDR
Features suggestive of NASH are more frequently observed in HCC arising in patients with CC than in age- and sex-matched HCC patients of well-defined viral or alcoholic etiology. Expand
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes
TLDR
Normal ALT is not a valuable criterion to exclude patients from liver biopsy, and Alterations in glucose metabolism and insulin resistance in subjects with normal ALT should also be considered in the selection of NAFLD cases for histological assessment of disease severity and progression. Expand
A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease
TLDR
Limited histological data support an association between improved aminotransferases and biopsy findings, which require confirmation in a double-blind trial with appropriate statistical power based on liver histology. Expand
...
1
2
3
4
5
...